AJANTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | AJANTPHARM | Market Cap | 36,791 Cr. | Current Price | 2,944 ₹ | High / Low | 3,228 ₹ |
| Stock P/E | 39.0 | Book Value | 330 ₹ | Dividend Yield | 0.95 % | ROCE | 33.0 % |
| ROE | 25.7 % | Face Value | 2.00 ₹ | DMA 50 | 2,893 ₹ | DMA 200 | 2,720 ₹ |
| Chg in FII Hold | -0.56 % | Chg in DII Hold | 0.68 % | PAT Qtr | 245 Cr. | PAT Prev Qtr | 250 Cr. |
| RSI | 48.8 | MACD | 36.2 | Volume | 99,549 | Avg Vol 1Wk | 1,63,802 |
| Low price | 2,022 ₹ | High price | 3,228 ₹ | PEG Ratio | 4.91 | Debt to equity | 0.01 |
| 52w Index | 76.4 % | Qtr Profit Var | -2.94 % | EPS | 75.5 ₹ | Industry PE | 27.2 |
📊 AJANTPHARM shows moderately strong technicals for intraday trading. RSI at 48.8 indicates neutral momentum, while MACD is positive (36.2), suggesting bullish sentiment. Current price (2,944 ₹) is above both 50 DMA (2,893 ₹) and 200 DMA (2,720 ₹), reflecting short-term strength. However, intraday volume (99.5K) is lower than the 1-week average (163.8K), which may limit sharp moves.
💡 Optimal Buy Price: 2,930–2,950 ₹ (near support zone)
🎯 Profit-Taking Levels: 3,020–3,080 ₹ (short-term resistance)
🛑 Stop-Loss: 2,910 ₹ (recent support)
⏱️ If already holding: Exit near 3,020–3,050 ₹ if momentum weakens or volume drops, as upside is capped by resistance despite positive MACD.
Positive
- Strong ROCE (33.0%) and ROE (25.7%) highlight excellent capital efficiency.
- Debt-to-equity ratio of 0.01 indicates virtually debt-free operations.
- EPS of 75.5 ₹ supports strong profitability.
- Trading above both 50 DMA and 200 DMA confirms bullish trend.
Limitation
- High P/E of 39 compared to industry PE (27.2) suggests premium valuation.
- Quarterly PAT declined slightly (245 Cr vs 250 Cr), showing earnings pressure.
- PEG ratio of 4.91 indicates overvaluation relative to growth.
- FII holdings decreased by 0.56%, showing reduced foreign investor confidence.
Company Negative News
- No major negative news reported, but slight earnings decline is a concern.
Company Positive News
- DII holdings increased by 0.68%, reflecting domestic investor confidence.
- Strong fundamentals with high ROCE and ROE continue to support valuation.
Industry
- Industry PE at 27.2 is lower than company PE (39), suggesting AJANTPHARM trades at a premium.
- Pharma sector remains resilient with steady growth outlook.
Conclusion
⚖️ AJANTPHARM is fundamentally strong and technically supportive for intraday trades today. Entry near 2,930–2,950 ₹ with a stop-loss at 2,910 ₹ is advisable. Upside potential is 3,020–3,080 ₹, making it a relatively good intraday candidate with moderate risk.